ENANTA PHARMACEUTICALS, INC Income (Loss) from Continuing Operations before Income Taxes, Domestic
ENANTA PHARMACEUTICALS, INC (ENTA) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $9.63 million for the 12-month period ending 2013-09-30, per its 10-K filed 2013-12-18.
Discontinued › Income Statement
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2013-12-18
- ENANTA PHARMACEUTICALS, INC income (loss) from continuing operations before income taxes, domestic for fiscal 2013 was $9.63M, a 55.01% decline from fiscal 2012.
- ENANTA PHARMACEUTICALS, INC income (loss) from continuing operations before income taxes, domestic for fiscal 2012 was $21.40M, a 0.42% increase from fiscal 2011.
- ENANTA PHARMACEUTICALS, INC income (loss) from continuing operations before income taxes, domestic for fiscal 2011 was $21.31M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2013-09-30 | $9.63M 10-K · filed 2013-12-18 |
| 2012-09-30 | $21.40M 10-K · filed 2013-12-18 |
| 2011-09-30 | $21.31M 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |